FR3019464B1 - Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent - Google Patents

Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent

Info

Publication number
FR3019464B1
FR3019464B1 FR1453046A FR1453046A FR3019464B1 FR 3019464 B1 FR3019464 B1 FR 3019464B1 FR 1453046 A FR1453046 A FR 1453046A FR 1453046 A FR1453046 A FR 1453046A FR 3019464 B1 FR3019464 B1 FR 3019464B1
Authority
FR
France
Prior art keywords
oxazino
benzotriazine
dione
fluorophenyl
cyclopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1453046A
Other languages
English (en)
Other versions
FR3019464A1 (fr
Inventor
Sylvie Bretin
Maria Pueyo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Servier SAS
Original Assignee
Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51383800&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR3019464(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratoires Servier SAS filed Critical Laboratoires Servier SAS
Priority to FR1453046A priority Critical patent/FR3019464B1/fr
Priority to PCT/FR2015/050879 priority patent/WO2015155451A1/fr
Priority to PE2016001884A priority patent/PE20170332A1/es
Priority to JP2016561308A priority patent/JP2017510597A/ja
Priority to SG11201608152RA priority patent/SG11201608152RA/en
Priority to MX2016013118A priority patent/MX2016013118A/es
Priority to CA2944750A priority patent/CA2944750A1/fr
Priority to MA039493A priority patent/MA39493A/fr
Priority to KR1020167030840A priority patent/KR20160134854A/ko
Priority to EP15719502.5A priority patent/EP3129059A1/fr
Priority to EA201692006A priority patent/EA201692006A1/ru
Priority to CN201580018480.7A priority patent/CN106163563A/zh
Priority to MDA20160115A priority patent/MD20160115A2/ro
Priority to US15/302,245 priority patent/US20170027949A1/en
Priority to RU2016143382A priority patent/RU2016143382A/ru
Priority to AU2015245416A priority patent/AU2015245416A1/en
Publication of FR3019464A1 publication Critical patent/FR3019464A1/fr
Publication of FR3019464B1 publication Critical patent/FR3019464B1/fr
Application granted granted Critical
Priority to CL2016002518A priority patent/CL2016002518A1/es
Priority to PH12016501982A priority patent/PH12016501982A1/en
Priority to ZA2016/06873A priority patent/ZA201606873B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
FR1453046A 2014-04-07 2014-04-07 Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent Active FR3019464B1 (fr)

Priority Applications (19)

Application Number Priority Date Filing Date Title
FR1453046A FR3019464B1 (fr) 2014-04-07 2014-04-07 Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent
EA201692006A EA201692006A1 (ru) 2014-04-07 2015-04-03 НОВАЯ АССОЦИАЦИЯ 8-ЦИКЛОПРОПИЛ-3-[2-(3-ФТОРФЕНИЛ)ЭТИЛ]-7,8-ДИГИДРО-3Н-[1,3]ОКСАЗИНО[6,5-g][1,2,3]БЕНЗОТРИАЗИН-4,9-ДИОНА И ИНГИБИТОРА АЦЕТИЛХОЛИНЭСТЕРАЗЫ, А ТАКЖЕ СОДЕРЖАЩИЕ ЕЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
MDA20160115A MD20160115A2 (ro) 2014-04-07 2015-04-03 Combinaţie nouă dintre 8-ciclopropil-3-[2-(3-fluorofenil)etil]-7,8-dihidro-3H-[1,3]oxazino[6,5-g][1,2,3]benzotriazin-4,9-dionă şi un inhibitor al acetilcolinesterazei şi compoziţii farmaceutice care o conţin
JP2016561308A JP2017510597A (ja) 2014-04-07 2015-04-03 ８−シクロプロピル−３−［２−（３−フルオロフェニル）エチル］−７，８−ジヒドロ−３Ｈ−［１，３］オキサジノ［６，５−ｇ］［１，２，３］ベンゾトリアジン−４，９−ジオンとアセチルコリンエステラーゼインヒビターとの新規な併用、及びこれを含有する医薬組成物
SG11201608152RA SG11201608152RA (en) 2014-04-07 2015-04-03 Novel combination between 8-cyclopropyl-3-[2-(3-fluorophenyl) ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-dioneand an acetylcholinesterase inhibitor, and pharmaceutical compositions containing same
MX2016013118A MX2016013118A (es) 2014-04-07 2015-04-03 Nueva asociacion entre la8-ciclopropil-3-[2-(3-flurofenil)etil]-7, 8-dihidro-3h-[1,3]oxazino[6,5-g][1,2,3]benzotriazina-4,9-diona y un inhibidor de la acetilcolinesterasay las composiciones farmaceuticas que la contienen.
CA2944750A CA2944750A1 (fr) 2014-04-07 2015-04-03 Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase, et compositions pharmaceutiques contenant celle-ci
MA039493A MA39493A (fr) 2014-04-07 2015-04-03 Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl) ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase, et compositions pharmaceutiques contenant celle-ci
KR1020167030840A KR20160134854A (ko) 2014-04-07 2015-04-03 8-사이클로프로필-3-[2-(3-플루오로페닐)에틸]-7,8-디하이드로-3h-[1,3]옥사지노[6,5-g][1,2,3]벤조트리아진-4,9-디온과 아세틸콜린에스테라제 억제제 간의 신규한 회합물, 및 이를 함유하는 약제 조성물
EP15719502.5A EP3129059A1 (fr) 2014-04-07 2015-04-03 Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl) ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase, et compositions pharmaceutiques contenant celle-ci
PCT/FR2015/050879 WO2015155451A1 (fr) 2014-04-07 2015-04-03 Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl) ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase, et compositions pharmaceutiques contenant celle-ci
CN201580018480.7A CN106163563A (zh) 2014-04-07 2015-04-03 8‑环丙基‑3‑[2‑(3‑氟苯基)乙基]‑7,8‑二氢‑3H‑[1,3]噁嗪并[6,5‑g][1,2,3]苯并三嗪‑4,9‑二酮与乙酰胆碱酯酶抑制剂的新组合以及包含它的药物组合物
PE2016001884A PE20170332A1 (es) 2014-04-07 2015-04-03 NUEVA ASOCIACION ENTRE LA 8-CICLOPROPIL-3-[2-(3-FLUOROFENIL)ETIL]-7,8-DIHIDR0-3H-[1,3]0XAZIN0[6,5-g][1,2,3]BENZOTRIAZINA-4,9-DIONA Y UN INHIBIDOR DE LA ACETILCOLINESTERASA Y LAS COMPOSICIONES FARMACEUTICAS QUE LA CONTIENEN
US15/302,245 US20170027949A1 (en) 2014-04-07 2015-04-03 ASSOCIATION BETWEEN 8-CYCLOPROPYL-3-[2-(3-FLUOROPHENYL)ETHYL]-7,8-DIHYDRO-3H-[1,3]OXAZINO[6,5-g][1,2,3]BENZOTRIAZINE-4,9-DIONE AND AN ACETYLCHOLINESTERASE INHIBITOR, AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
RU2016143382A RU2016143382A (ru) 2014-04-07 2015-04-03 НОВАЯ АССОЦИАЦИЯ 8-ЦИКЛОПРОПИЛ-3-[2-(3-ФТОРФЕНИЛ)ЭТИЛ]-7, 8-ДИГИДРО-3H-[1, 3]ОКСАЗИНО[6, 5-g][1, 2, 3]БЕНЗОТРИАЗИН-4, 9-ДИОНА И ИНГИБИТОРА АЦЕТИЛХОЛИНЭСТЕРАЗЫ, А ТАКЖЕ СОДЕРЖАЩИЕ ЕЕ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ
AU2015245416A AU2015245416A1 (en) 2014-04-07 2015-04-03 Novel combination between 8-cyclopropyl-3-[2-(3-fluorophenyl) ethyl]-7,8-dihydro-3H-[1,3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-dione and an acetylcholinesterase inhibitor, and pharmaceutical compositions containing same
CL2016002518A CL2016002518A1 (es) 2014-04-07 2016-10-04 Combinación farmacéutica de 8-ciclopropil-3-[2-(3-fluorofenil)etil]-7,8-dihidro-3h-[1,3]oxazino[6,5-g][1,2,3] benzotriazina-4,9-diona y un inhibidor de acetilcolinesterasa; composición farmacéutica; y uso para el tratamiento de los trastornos cognitivos asociados con el envejecimiento cerebral y enfermedades neurodegenerativas.
PH12016501982A PH12016501982A1 (en) 2014-04-07 2016-10-05 NEW ASSOCIATION BETWEEN 8-CYCLOPROPYL-3-[2-(3-FLUOROPHENYL)ETHYL]-7,8-DIHYDRO-3H-[1,3]OXAZINO[6,5-g][1,2,3]BENZOTRIAZINE-4,9-DIONE AND AN ACETYLCHOLINESTERASE INHIBITOR, AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
ZA2016/06873A ZA201606873B (en) 2014-04-07 2016-10-06 Novel combination between 8-cyclopropyl-3-[2-(3-fluorophenyl) ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g][1,2,3]benzotriazine-4,9-dione and an acetylcholinesterase inhibitor, and pharmaceutical compositions containing same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1453046A FR3019464B1 (fr) 2014-04-07 2014-04-07 Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent

Publications (2)

Publication Number Publication Date
FR3019464A1 FR3019464A1 (fr) 2015-10-09
FR3019464B1 true FR3019464B1 (fr) 2016-05-06

Family

ID=51383800

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1453046A Active FR3019464B1 (fr) 2014-04-07 2014-04-07 Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent

Country Status (19)

Country Link
US (1) US20170027949A1 (fr)
EP (1) EP3129059A1 (fr)
JP (1) JP2017510597A (fr)
KR (1) KR20160134854A (fr)
CN (1) CN106163563A (fr)
AU (1) AU2015245416A1 (fr)
CA (1) CA2944750A1 (fr)
CL (1) CL2016002518A1 (fr)
EA (1) EA201692006A1 (fr)
FR (1) FR3019464B1 (fr)
MA (1) MA39493A (fr)
MD (1) MD20160115A2 (fr)
MX (1) MX2016013118A (fr)
PE (1) PE20170332A1 (fr)
PH (1) PH12016501982A1 (fr)
RU (1) RU2016143382A (fr)
SG (1) SG11201608152RA (fr)
WO (1) WO2015155451A1 (fr)
ZA (1) ZA201606873B (fr)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005208871B2 (en) * 2004-01-26 2010-04-01 Cortex Pharmaceuticals Inc. Enhancement of ampakine-induced facilitation of synaptic responses by cholinesterase inhibitors
SG163545A1 (en) * 2007-01-03 2010-08-30 Servier Lab 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses
WO2009038752A2 (fr) * 2007-09-20 2009-03-26 Cortex Pharmaceuticals, Inc. 1,2,3-triazine-4-ones 3-substituées et 1,3-pyrimidinones 3-substituées pour améliorer les réponses synaptiques glutamatergiques

Also Published As

Publication number Publication date
MA39493A (fr) 2015-10-15
ZA201606873B (en) 2018-11-28
CN106163563A (zh) 2016-11-23
SG11201608152RA (en) 2016-11-29
WO2015155451A1 (fr) 2015-10-15
EP3129059A1 (fr) 2017-02-15
US20170027949A1 (en) 2017-02-02
AU2015245416A1 (en) 2016-10-27
RU2016143382A (ru) 2018-05-07
CL2016002518A1 (es) 2017-03-17
JP2017510597A (ja) 2017-04-13
PH12016501982A1 (en) 2017-01-09
KR20160134854A (ko) 2016-11-23
EA201692006A1 (ru) 2017-02-28
FR3019464A1 (fr) 2015-10-09
MX2016013118A (es) 2017-01-20
CA2944750A1 (fr) 2015-10-15
PE20170332A1 (es) 2017-04-15
MD20160115A2 (ro) 2017-02-28

Similar Documents

Publication Publication Date Title
EP3473270A4 (fr) Conjugué anticorps-médicament
IL254714B (en) History of quinoline and pharmaceutical preparations containing them
WO2016094837A3 (fr) Anticorps anti-c10orf54 et leurs utilisations
EP3181559A4 (fr) Dérivé 2-(aniline 2,4,5-substituée)pyrimidine, composition pharmaceutique et leur utilisation
WO2015168019A3 (fr) Conjugués médicament-anticorps anti-ptk7
CL2018000565A1 (es) Compuestos derivados de piridinona dicarboxamida, inhibidores de bromodominio; composicion farmaceutica; combinacion farmaceutica; utiles en el tratamiento de enfermedades autoinmunitarias, inflamatorias, virales y cancer, entre otras.
GB201807968D0 (en) Eutectic extract formation and purification
EP3159338A4 (fr) Dérivé de pyrimidine-2,4-diamine et composition pharmaceutique anticancéreuse en contenant en tant que principe actif
EP3416647A4 (fr) Iminopyrimidinones substituées par n3 à titre d'agents antipaludéens
IL264386A (en) New formulations and mixtures of cannabis tablets and methods of making them
PT3580208T (pt) Derivados de 2-(3-(1h-benzo[d]imidazol-1-il)propil)piperidin-3-ol e compostos relacionados como inibidores de prs para tratamento de, por exemplo, cancro
EP3094291A4 (fr) Treillis formant stent pour le canal de schlemm
EP3661489A4 (fr) Composition de microcapsule pharmaceutique flottable
PL3452075T3 (pl) Oftalmiczna kompozycja farmaceutyczna
EP3135667A4 (fr) Nouveaux dérivés de 2-amino-pyridine et 2-amino-pyrimidine et leur utilisation médicinale
PL3421038T3 (pl) Związek naftyrydyny, kompozycja farmaceutyczna i ich zastosowanie
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
WO2017074798A3 (fr) Co-agonistes à action longue durée des récepteurs du glucagon et du glp-1
WO2018053552A3 (fr) Isoquinolidinobenzodiazépines
EP3546449A4 (fr) Dérivé de pipéridine -2,6-dicétone et traitement de la maladie de crohn
EP3291818A4 (fr) Compositions et procédés pour l'administration d'agents thérapeutiques dans le côlon
GB2590189B (en) Lycorine derivative, and pharmaceutical composition and use thereof
ZA201908006B (en) Targeted drug rescue with novel compositions, combinations, and methods thereof
EP3199163A4 (fr) Composition de doxycycline dans des liposomes pour la prévention, l'amélioration et/ou le traitement de pathologies oculaires
EP3441075A4 (fr) Composition d'huile essentielle administrée par voie orale et son utilisation

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4